The Scale of a Silent Health Emergency
Australia is confronting one of the most complex public health challenges of the post-pandemic era: an estimated 870,000 Australians — roughly 5.6% of those who have contracted COVID-19 — are now living with Long COVID, a condition characterised by debilitating fatigue, cognitive impairment, and chronic pain that persists for months or even years after the initial infection. Despite these staggering figures, the nation’s healthcare system remains ill-equipped to identify, treat, and support this growing patient population.
The term “Long COVID” encompasses a spectrum of post-acute sequelae of COVID-19 (PASC), a condition the World Health Organization defines as symptoms continuing for at least three months after the acute phase of infection. In Australia, the prevalence varies significantly across demographics, with some studies suggesting that 5-10% of all people who contract COVID-19 will develop Long COVID, while other research indicates that nearly 1 in 10 Australians who have had the virus continue to live with the condition.
A Healthcare System Stretched to Breaking Point
A comprehensive global guideline review published in BMC Health Services Research in March 2026 revealed that Australian service delivery remains fragmented, with a growing number of primary health practitioner-led private services operating largely under a fee-for-service model. This has created significant variations in access and affordability, leaving many patients — particularly those in rural, remote, and lower socioeconomic areas — without consistent care pathways.
The review further highlighted a fundamental challenge: statistical invisibility. Without an activated diagnostic code for Long COVID, healthcare services cannot reliably identify or follow people living with the condition, severely limiting both surveillance and service planning. Many hospital-based outpatient clinics have been absorbed into existing chronic-disease services, resulting in fragmented and uncoordinated care that fails to address the complex, multi-system nature of Long COVID.
The Economic and Workforce Toll
The financial implications of Long COVID are equally sobering. Research published in the Medical Journal of Australia estimated that Long COVID-related reductions in labour supply could cost the Australian economy approximately $9.6 billion — equivalent to 0.5% of GDP — between 2022 and 2024. The study projected that working hours lost would be highest among people aged 30–49 years, representing a significant drain on the nation’s most productive demographic.
Emerge Australia, the nation’s leading advocacy organisation for ME/CFS and Long COVID, has reported that ME/CFS alone costs the Australian economy an estimated $14.5 billion annually, and almost 50% of Long COVID patients are known to transition to ME/CFS. With an additional 250,000 Australians already living with ME/CFS, the combined burden represents a looming workforce crisis that policymakers can no longer afford to ignore.
The Human Cost Behind the Numbers
For the individuals behind these statistics, the reality is far more personal. A study published in BMJ Open in May 2026 documented the experiences of Long COVID patients in Adelaide, identifying challenges including lack of validation, delayed multidisciplinary care, mental health deterioration, and difficulties navigating the healthcare system. These challenges were described as having particular relevance for older adults, who may also be managing comorbidities and social vulnerabilities.
Dr Emma Tippett, Director of Clinic Nineteen — a pioneering national telehealth clinic that has served over 1,500 people across Australia — has been vocal about the cost of inaction. “The cost of doing nothing vastly outweighs the costs of acting,” she told a parliamentary meeting in March 2026. Her sentiment reflects a growing consensus among clinicians and researchers that Australia’s current approach to Long COVID is both economically unsustainable and morally indefensible.
A Path Forward — but at What Speed?
The Australian Government has taken initial steps to address the crisis. In 2026, the Medical Research Future Fund (MRFF) announced $23 million in funding** for research into PASC subtypes, biological pathways, and scalable integrated care approaches. This investment forms part of a broader **$50 million commitment to Long COVID research announced by the Minister for Health and Aged Care.
However, as the BMC Health Services Research review noted, Australia remains behind comparable nations such as Canada, the United Kingdom, and the United States in developing and implementing the integrated, multidisciplinary care models recommended internationally. The forthcoming NHMRC-led clinical practice guideline for ME/CFS, expected by the end of 2027, represents an important policy milestone, but for the hundreds of thousands of Australians currently living with Long COVID, that timeline may feel impossibly distant.
